Needham & Company Downgrades OncoGenex Pharmaceuticals (OGXI) to Hold

Needham & Company downgraded OncoGenex Pharmaceuticals (NASDAQ: OGXI) from Strong Buy to Hold with a price target of $14.00.

Analyst Chad Messer comments, "OncoGenex reported negative top line data from the pivotal SYNERGY trial testing custersin on top of 1st line chemotherapy with docetaxel in patients with metastatic castrate resistant prostate cancer (CRPC). Custersin failed to significantly increase overall survival (OS) in this study. These results are surprising given the highly significant 7 month benefit seen in an earlier, nearly identically designed, Phase II trial. However, we see no read through from SYNERGY's failure to other ongoing programs at OGXI. We continue to believe shares are significantly undervalued."

For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.

Shares of OncoGenex Pharmaceuticals closed at $9.70 yesterday.

You May Also Be Interested In

• BofA Securities Upgrades Etsy (ETSY) to Buy, 'Still Room to Run'
• Target (TGT) PT Raised to $175 at Guggenheim
• Needham Reiterates Buy Rating on Bandwidth Inc. (BAND)